---
title: "Pyxis Oncology surges 16% on 39% response rate in MICVO Phase I update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306163646.md"
description: "Pyxis Oncology rose 16.31% to $1.64 after updated Phase I MICVO data showed a 39% response rate and 6.7-month mPFS."
datetime: "2026-11-19T20:31:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306163646.md)
  - [en](https://longbridge.com/en/news/306163646.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306163646.md)
generator: "portal-rs"
---

# Pyxis Oncology surges 16% on 39% response rate in MICVO Phase I update

Pyxis Oncology (PYXS.US) surged more than **16%** during regular trading to **$1.64**.

The company reported updated Phase I trial results for MICVO in previously treated patients with recurrent or metastatic head and neck cancer, showing a confirmed response rate of **39%**, median progression-free survival of **6.7 months** and median duration of response of **9.2 months** among 33 second-line or later patients.

Pyxis Oncology said clinical activity was consistent across patient subgroups with a manageable safety profile, noting the data may support its planned mid-2027 launch of the global Phase III Headliner trial.

Separately, the company narrowed its third-quarter net loss to **$19.98 million**. Previously disclosed MICVO monotherapy data in advanced head and neck cancer showed a confirmed response rate of **36%** and median progression-free survival of **6.2 months**.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [PYXS.US](https://longbridge.com/en/quote/PYXS.US.md)

## Related News & Research

- [PYXS: MICVO showed durable responses in phase 1, supporting a planned global Phase 3 trial](https://longbridge.com/en/news/306107284.md)
- [William Blair upgrades Pyxis Oncology to Outperform from Market Perform](https://longbridge.com/en/news/306274949.md)
- [Guggenheim Remains a Buy on Pyxis Oncology (PYXS)](https://longbridge.com/en/news/306281515.md)
- [AI solves 167-year-old maths problem, Anthropic researcher claims](https://longbridge.com/en/news/306318851.md)
- [Anthropic lacks ‘basic moral compass’, say publishers](https://longbridge.com/en/news/306295252.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**